14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $3.81 $4.85 Wednesday, 1st May 2024 NVAX stock ended at $4.67. This is 7.85% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 11.89% from a day low at $4.29 to a day high of $4.80.
90 days $3.53 $6.05
52 weeks $3.53 $11.36

Historical Novavax Inc prices

Date Open High Low Close Volume
Feb 20, 2024 $4.16 $4.23 $4.08 $4.13 3 250 903
Feb 16, 2024 $4.22 $4.31 $4.11 $4.16 4 097 506
Feb 15, 2024 $4.11 $4.35 $4.07 $4.30 6 589 296
Feb 14, 2024 $3.97 $4.15 $3.87 $4.10 5 828 792
Feb 13, 2024 $4.03 $4.04 $3.81 $3.90 7 182 792
Feb 12, 2024 $4.09 $4.34 $4.00 $4.15 7 347 907
Feb 09, 2024 $3.83 $4.14 $3.75 $4.03 7 438 190
Feb 08, 2024 $3.68 $3.80 $3.60 $3.79 4 572 278
Feb 07, 2024 $3.93 $3.93 $3.75 $3.78 4 656 732
Feb 06, 2024 $3.77 $3.95 $3.70 $3.93 4 576 628
Feb 05, 2024 $3.83 $3.86 $3.53 $3.76 8 874 804
Feb 02, 2024 $4.01 $4.02 $3.82 $3.93 8 131 004
Feb 01, 2024 $4.05 $4.09 $3.99 $4.02 4 729 047
Jan 31, 2024 $4.01 $4.24 $3.95 $4.00 7 595 982
Jan 30, 2024 $4.18 $4.20 $4.02 $4.03 5 486 804
Jan 29, 2024 $4.07 $4.20 $4.01 $4.19 5 657 198
Jan 26, 2024 $4.17 $4.23 $3.98 $4.06 5 161 123
Jan 25, 2024 $4.07 $4.19 $4.04 $4.10 5 299 946
Jan 24, 2024 $4.32 $4.35 $4.02 $4.05 4 946 301
Jan 23, 2024 $4.32 $4.36 $4.12 $4.26 4 804 698
Jan 22, 2024 $4.06 $4.29 $4.02 $4.18 6 117 213
Jan 19, 2024 $4.11 $4.12 $3.99 $4.05 4 804 459
Jan 18, 2024 $4.11 $4.15 $4.01 $4.11 6 245 461
Jan 17, 2024 $4.22 $4.25 $4.15 $4.21 4 768 216
Jan 16, 2024 $4.43 $4.48 $4.28 $4.34 6 955 506
Click to get the best stock tips daily for free!

About Novavax Inc

Novavax Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria... NVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT